Business and Finance

The expansion of TrumpRx will increase price transparency and purchase options of generic drugs for cash-paying patients.

At the Doceree Makers Summit, leaders from Sanofi, Bristol Myers Squibb, Eli Lilly, and others backed a new pharma marketing operating model to replace fragmented legacy softwares.

In today’s Pharma Pulse, FDA leadership changes with Makary’s resignation, Lilly shares new Zepbound and GLP-1 data, and new study data on prior authorization reform outlook.

FDA commissioner Marty Makary is planning to resign today, according to sources close to the White House.

Angelini Pharma is acquiring Catalyst Pharmaceuticals in a $4.1 billion transaction that expands its presence in the US rare disease market and adds a portfolio of neuromuscular and neurological therapies.

Will Shrank, MD, explains how the specialty pharma pipeline could pose access risks in the future.

In this week's Pharma Pulse, Eli Lilly opens its new genetic medicine plant, Bayer acquires Perfuse Therapeutics, and more.

The facility opening corresponds with a new $4.5 billion capital commitment across two of Lilly's three sites in Lebanon, Indiana.

Kim Plesnarski explains what the biggest inefficiencies are in specialty pharma partnerships.

GoodRx now offers oral Ozempic as an alternative to injectable GLP-1 therapies.

Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around specialty medicines.

Avalere Health analysts map the converging pressures reshaping the drug pricing and distribution landscape ahead of November.

Rahul Shah and Mack MacKenzie explain how to unlock the ROI that rules-based systems have left on the table.

Pharma importers can apply for tariff reimbursements through the US Customs and Border Protection’s online portal.

Lilly’s $7B deal for Kelonia aims to turn complex cell therapy into a simple injection, bypassing the slow, costly lab work of current cancer treatments.

Fran Gregory, VP of Emerging Therapies at Cardinal Health, discusses key findings from the company's 2026 Advanced Therapy Report.

Charley Maxwell explains why Annex 21 is not just a regulatory hurdle, but a key commercial risk point.

Roel van den Akker examines how the industry might evolve its trade, distribution, and payer strategies to scale GLP-1s for mass demand.

In a Q&A, Traci Miller discusses the evolving role of hub services as well as their commercial value.

Lilly's Foundayo and Zepbound KwikPen are now available on GoodRx for self-pay access.

Amber Hussain-Siddique says operational discipline in inventory and logistics is the vital, yet overlooked, key to sustaining low-cost generic drug supplies in the U.S.

New Benefit 360 and Direct Fund models aim to bridge the gap between clinical eligibility and employer-sponsored coverage.

Jay Bregman, founder and CEO of Andel, discusses how employers are managing rising costs for prescription benefits and how pharma companies are shifting their distribution patterns.

Kroger will offer the Zepbound KwikPen at its participating retail pharmacies.